FDA

Is the FDA Becoming Too Loose? Or is There a Bigger Question We Need...

Razib Khan is a geneticist who serves as Director of Scientific Content at Insitome. He also co-hosts a podcast that uses scientific tools to...
Cancer

Startup: BostonGene—Personalizing & Transforming Cancer Care with Molecular Level Patient Analysis

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s...
UT Southwestern

CPRIT & UT Southwestern Lure Oncology R&D Talent to Lone Star State

UT Southwestern’s Peloton Therapeutics was just acquired by Merck for up to $2.1 billion, if certain milestones and performance KPIs are met. Research and...
Biotechnology

Merck’s Peloton Therapeutics Purchase: Taking the Novel UT Southwestern to the Global Stage

TrialSite News covered the Merck acquisition of Peloton Therapeutics (Peloton). As the Dallas TX-based venture published an S-1 in anticipation of going public, we offered...
Grant money

Immuno-Oncology Venture Atreca Files IPO for $100 Million Capital Raise to Leverage Stanford Invention

Redwood City, CA-based Atreca, a preclinical biotech development immunotherapies for solid tumors, recently filed an initial public offering (IPO) with the SEC for up...

Breakdown of the  FDA’s Real-Time Oncology Review (RTOR) Pilot Program

TrialSite News recently reported on the approval of Novartis’ alpelisib for treatment of postmenopausal women, and men with positive HR-positive, HER2-negative, PIK3CA-mutated, advanced metastatic...
Velocity

Velocity Clinical Research Expands Clinical Trial Capabilities Through Organic Growth

Durham, N.C. – May 23, 2019 – Velocity Clinical Research, in line with its planned strategy to grow organically as well as by acquisition,...
Big Pharmas Join Verily

Big Pharmas Join Verily (Google) Project Baseline Alliance: Their Processes & Systems Must Keep...

Google-owned venture Verily released a press release announcing a strategic biopharmaceutical alliance with major biopharma including: Novartis Otsuka Pfizer Sanofi TrialSite News considers this a...
Investor Article

Investor Update

Drug & Device Development Funding Flows As we head toward June and toward the mid-point of 2019, TrialSite News was requested by a few readers...
Atopic Dermatitis

Atopic Dermatitis and Dupilumab: A Literature Review for Side Effects

TrialSite News reported on a recent Stanford University School of Medicine study concluding that nearly 25% of a segment of adults with atopic dermatitis...